Moleculin (MBRX) CEO Walter Klemp Buys Shares, Receives Warrants

What Happened

• Walter V. Klemp, CEO, President and a director of Moleculin Biotech (MBRX), participated in a public offering on Aug 3, 2026. He purchased 533,333 shares of common stock and was issued Series I warrants to purchase 1,599,999 additional shares (3 warrants per share).
• The combined purchase price was $0.75 per one share plus its three accompanying warrants, meaning the cash outlay was approximately $399,999.75 (≈ $400K). This is a purchase and an award of derivatives (warrants), which is generally a bullish/ownership-increasing action rather than a sale.

Key Details

• Transaction date: 2026-08-03 (filed on 2026-08-05).
• Purchase: 533,333 common shares acquired at a combined package price of $0.75 per share + 3 warrants.
• Derivative award: 1,599,999 Series I warrants (3 warrants per share purchased) — these are rights to buy common shares later; exercise price and expiration not provided in the excerpt.
• Approximate cash paid: $533,333 × $0.75 = $399,999.75.
• Shares owned after transaction: not stated in the provided filing excerpt.
• Filing timeliness: filed Aug 5 for an Aug 3 transaction — appears timely (not marked late).

Context

• The warrants are derivative instruments that allow Klemp to acquire more shares in the future if he exercises them under their terms; they are not immediate common shares until exercised.
• This was a direct purchase in a public offering (not a secondary sale or gift), which increases the insider’s potential stake/exposure to the company.